Regeneron’s EYLEA has positive results in phase 3
Our expert's opinion
"Regeneron is currently developing a drug called EYLEA that treats non-proliferative diabetic retinopathy (NPDR). The product is now going through phase III and it shows very satisfying results, such as a reduction of 75% of the risk of vision loss. The product is efficient, even with doses given only every 16 weeks. I'm really afraid of one day developing a condition, such as NPDR or Glaucoma, that would reduce my vision. Therefore, I’m always happy that these kind of products are in development."
- Antoine Desprez, Associate Consultant
Regeneron reports positive data from Phase 3 EYLEA trial in diabetic retinopathy
Regeneron Pharmaceuticals (NASDAQ:REGN) presents positive detailed one-year results from the Phase 3 PANORAMA trial evaluating EYLEA (aflibercept) Injection in patients with moderately severe to severe non-proliferative diabetic retinopathy (NPDR) at the Angiogenesis, Exudation, and Degeneration 2019 symposium.
The trial confirmed that moderately severe and severe NPDR is not a benign condition, with patients at high risk of rapidly progressing to vision-threatening events.
In untreated patients with severe NPDR, 53% developed these events at one year. Most importantly, EYLEA treatment reduced the risk of these events by ~74% compared to sham injection.
This efficacy was seen even with an every 16-week treatment regimen after loading doses.
Adverse events were consistent with the known profile of EYLEA.
A sBLA for EYLEA in diabetic retinopathy has been accepted for review by the FDA with a target action date of May 13, 2019.
Source: Seeking Alpha
Other insights in Pharmaceutical Affairs
Read our insight
Revolutionizing Pharmaceutical Manufacturing
How A.I. is Transforming the Industry in Europe